Posted on 2/13/18
Teva Pharmaceuticals Could Bounce Back To $20
Just when it looked as though Teva Pharmaceuticals (TEVA) would settle at $10 in November 2017, the stock barely managed to hold the $11 mark and . . .
Posted on 2/13/18
Teva's Luck Continues To Run Out
Teva (TEVA) has been performing poorly over the last few years as its generics business has been declining in sales. It managed to beat its fourth . . .
Posted on 2/13/18
Teva Stock Upgraded After Earnings: What You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking . . .
Posted on 2/13/18
Onconova Therapeutics Closes $10 Million Underwritten Public Offering
NEWTOWN, Pa., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug . . .
Posted on 2/12/18
Will Teva Pharmaceutical's Pain Be Mylan's Gain?
Teva Pharmaceutical (NYSE:TEVA) reported fourth-quarter financials this week that reflect a significant drop-off in demand for its best-selling drug, Copaxone, a widely used multiple sclerosis drug.Patents . . .
Posted on 2/12/18
Here's What Teva Pharmaceutical's Saying About Its Future
Teva Pharmaceutical Industries' (NYSE:TEVA) sales and profit are struggling because of pricing pressure, competition, and massive debt, and that's taking a toll on its shares. Can . . .
Posted on 2/12/18
Better Buy: Pfizer Inc. vs. GlaxoSmithKline plc
If your investing decisions were based solely on past performance, Pfizer Inc. (NYSE:PFE)would be the better stock to buy than GlaxoSmithKline plc (NYSE:GSK). Over the past . . .
Posted on 2/12/18
Oncobiologics Announces Term Extension of Series A Warrants
CRANBURY, N.J., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) (NASDAQ:ONSIW) (NASDAQ:ONSIZ) announced today an extension to the term for exercise of its publicly traded . . .
Posted on 2/11/18
Celgene Prices $4.5 Billion of Senior Unsecured Notes
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of four series of senior unsecured notes for an aggregate principal amount of $4.5 billion. Of . . .
Posted on 2/8/18
McKesson Pharmacy Systems and Creative Pharmacist Collaborate
MOON TOWNSHIP, Pa.--(BUSINESS WIRE)--McKesson Pharmacy Systems is pleased to announce a new partnership with Creative Pharmacist, a market leader in providing pharmacies with innovative clinical pharmacy . . .
Posted on 2/8/18
Johnson & Johnson: Waiting For A Better Yield
Johnson & Johnson's dividend yield has gradually been getting less competitive relative to its peers.While the company is still strong, competition in the pharmaceutical sector as . . .
Posted on 2/7/18
Janssen Enters Into Worldwide Collaboration With Theravance Biopharma
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today their entry into a worldwide collaboration with an affiliate of Theravance Biopharma, Inc. to develop TD-1473, . . .
Posted on 2/7/18
Retro Fitness Named Official Fitness Center of New York Yankees
Just in time for the start of baseball season, Retro Fitness is now the Official Fitness Center of the New York Yankees. In this multi-year partnership, . . .
Posted on 2/6/18
CBD For Life Recognized By Hollywood Beauty Awards As Product Of The Year - Skincare Award Winner
CBD For Life announced today that its highly innovative, natural and effective Cannabidiol (CBD) infused pain management and beauty products will receive the Product of the . . .
Posted on 2/5/18
Merck Company Inc. (MRK) Q4 2017 Earnings Conference Call Transcript
IMAGE SOURCE: THE MOTLEY FOOL.Merck & Company, Inc. (NYSE:MRK)Q4 2017 Earnings Conference CallFeb. 2, 2018, 8:00 a.m. ETContents:Prepared RemarksQuestions and AnswersCall ParticipantsPrepared Remarks:OperatorGood morning. My name . . .
Posted on 2/5/18
Where's Honeywell Headed In 2018?
Source: Honeywell Company ImageAmerican multinational conglomerate Honeywell (HON) had a great year in 2017. HON's stock price rose 32% outpacing peers United Technologies (UTX) and General . . .
Posted on 2/5/18
Honeywell Does It Again
Image creditHoneywell (HON) has been and continues to be my favorite industrial stock. The company’s ability to constantly improve not only revenue but margins as well . . .
Posted on 2/5/18
Merck: Keytruda Remains Key
Merck (MRK) has done relatively well since the last time I checked on the prospects for the shares (being the end of October) as they traded . . .
Posted on 2/5/18
Here's What Pfizer's Saying About Its Future
Pfizer Inc.'s (NYSE:PFE) fourth-quarter and full-year 2017 financial results suggest it's on its way toward becoming a growth stock again, and on its quarterly conference call, . . .
Posted on 2/4/18
Celgene Corp. Commences Tender Offer for Juno Therapeutics
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that its wholly-owned subsidiary, Blue Magpie Corporation, has commenced its previously announced tender offer for all outstanding shares of . . .
Posted on 2/2/18
Johnson & Johnson Or Pfizer For Dividends?
As the market continues to roar higher, the search for strong dividend yields for retirement portfolios becomes much tougher. But do we really need a 3% . . .
Posted on 2/1/18
ProgenyHealth Receives Investment From Sunstone Partners
ProgenyHealth, the only national company focused exclusively on neonatal intensive care unit (NICU) utilization and case management, announced today that it has received a significant growth . . .
Posted on 2/1/18
GlaxoSmithKline: Why This Diversified Stock Is A Definite Buy In 2018
GlaxoSmithKline (GSK) is one pharmaceutical company, very well diversified across businesses as well as geographic markets. The three-part inter-conditional transaction with Novartis, implemented way back in . . .
Posted on 2/1/18
Honeywell: The Stock Will Fly Higher In 2018
Honeywell (HON) is a must own stock in today's environment. The company recently reported better-than-expected Q4 2017 results, and management also raised their fiscal 2018 guidance . . .
Posted on 2/1/18
Is Celldex Therapeutics, Inc. (CLDX) a Buy?
Many biotech stocks posted strong performances in 2017. Celldex Therapeutics(NASDAQ:CLDX) wasn't one of them. The clinical-stage biotech saw its share price drop 20% last year. And . . .

